We analyzed the clinical outcome of lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients with visceral metastasis.
Ten patients of mCRPC with visceral metastasis were enrolled for one cycle of 177Lu-PSMA therapy.